7-Feb-2025
Globe Newswire (Sat, 8-Feb 11:34 PM ET)
Globe Newswire (Sat, 8-Feb 5:40 PM ET)
Globe Newswire (Sat, 8-Feb 3:55 PM ET)
Notable healthcare headlines for the week: Eli Lilly, Merck and Becton, Dickinson in focus
Seeking Alpha News (Sat, 8-Feb 2:25 PM ET)
Notable analyst calls this week: AMD, Skyworks and Nike stocks among top picks
Seeking Alpha News (Sat, 8-Feb 9:35 AM ET)
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
Benzinga (Fri, 7-Feb 4:00 PM ET)
Globe Newswire (Fri, 7-Feb 1:07 PM ET)
PRNewswire (Fri, 7-Feb 11:14 AM ET)
March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against REGN
PRNewswire (Fri, 7-Feb 5:45 AM ET)
Globe Newswire (Thu, 6-Feb 1:48 PM ET)
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Regeneron Pharmaceuticals trades on the NASDAQ stock market under the symbol REGN.
As of February 7, 2025, REGN stock price declined to $710.00 with 814,658 million shares trading.
REGN has a market cap of $78.02 billion. This is considered a Large Cap stock.
Last quarter Regeneron Pharmaceuticals reported $4 billion in Revenue and $12.07 earnings per share. This beat revenue expectation by $39 million and exceeded earnings estimates by $.88.
In the last 3 years, REGN traded as high as $1,211.20 and as low as $538.01.
The top ETF exchange traded funds that REGN belongs to (by Net Assets): VTI, VOO, QQQ, SPY, IVV.
REGN has underperformed the market in the last year with a return of -24.3%, while the SPY ETF gained +22.0%. In the last 3 month period, REGN fell short of the market, returning -13.9%, while SPY returned +1.2%. However, in the most recent 2 weeks REGN has outperformed the stock market by returning +5.1%, while SPY returned -1.2%.
REGN support price is $706.34 and resistance is $737.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that REGN shares will trade within this expected range on the day.